Sotera Health (NASDAQ:SHC) Price Target Cut to $20.00 by Analysts at Barclays

Sotera Health (NASDAQ:SHC) had its target price reduced by research analysts at Barclays from $22.00 to $20.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price target would suggest a potential upside of 20.59% from the stock’s current price.

Several other equities analysts have also recently commented on SHC. JPMorgan Chase & Co. cut Sotera Health from a “neutral” rating to an “underweight” rating and set a $17.00 price target for the company. in a report on Wednesday, October 14th. Piper Sandler reissued an “overweight” rating and set a $25.00 price objective on shares of Sotera Health in a report on Tuesday, September 8th. Weiss Ratings lowered Sotera Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 23rd. Wall Street Zen upgraded Sotera Health from a “buy” rating to a “strong-buy” rating in a research note on Sunday, October 25th. Finally, Citigroup lifted their price target on shares of Sotera Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.12.

Sotera Health Stock Performance

Sotera Health stock traded up $0.56 during mid-day trading on Wednesday, reaching $16.59. The company had a trading volume of 2,190,642 shares, compared to its average volume of 2,701,423. The company has a quick ratio of 2.55, a current ratio of 2.80 and a debt-to-equity ratio of 3.33. The firm has a market cap of $4.73 billion, a price-to-earnings ratio of 29.06 and a beta of 1.94. The company has a 50 day moving average of $18.42 and a 200-day moving average of $17.02. Sotera Health has a 52 week low of $13.09 and a 52 week high of $19.85.

Sotera Health (NASDAQ:SHC) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.02. The company had revenue of $324.89 million for the quarter, compared to the consensus estimate of $319.86 million. Sotera Health had a net margin of 13.44% and a return on equity of 40.12%. The business’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.26 EPS. On average, sell-side analysts expect that Sotera Health will post 0.87 EPS for the current fiscal year.

Insiders Place Their Bets

In other Sotera Health news, Chairman Michael B. Jr. Petras sold 850,000 shares of Sotera Health stock in a transaction on Monday, August 17th. The stock was sold at an average price of $18.50, for a total transaction of $15,725,000.00. Following the completion of the transaction, the chairman directly owned 3,969,393 shares of the company’s stock, valued at approximately $73,433,770.50. This trade represents a 17.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Michael P. Rutz sold 150,000 shares of the business’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $18.84, for a total transaction of $2,826,000.00. Following the completion of the sale, the insider owned 334,279 shares in the company, valued at $6,297,816.36. This represents a 30.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 1,294,515 shares of company stock valued at $23,999,528. Company insiders own 15.36% of the company’s stock.

Institutional Trading of Sotera Health

Several large investors have recently added to or reduced their stakes in SHC. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Sotera Health in the third quarter valued at approximately $29,000. Meeder Asset Management Inc. acquired a new stake in Sotera Health during the 2nd quarter valued at $37,000. Root Financial Partners LLC increased its holdings in Sotera Health by 217.5% during the 1st quarter. Root Financial Partners LLC now owns 2,124 shares of the company’s stock valued at $30,000 after purchasing an additional 1,455 shares in the last quarter. Provenance Wealth Advisors LLC bought a new position in Sotera Health in the 3rd quarter valued at $42,000. Finally, Nykredit A S acquired a new position in Sotera Health in the second quarter worth $50,000. 91.03% of the stock is owned by institutional investors.

Key Sotera Health News

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Q3 revenue rose 4.4% year over year to $324.9 million, topping analyst expectations of about $319.9 million. Adjusted EPS was $0.29 versus the $0.27 consensus and increased 12% year over year; adjusted EBITDA rose 3.9%. Sotera Health Q3 results
• Neutral Sentiment: Management reaffirmed its 2026 outlook: constant-currency revenue growth of 5.25%–6.75% and adjusted EBITDA growth of 5.75%–7.25%. It also provided fourth-quarter revenue guidance, though the supplied report did not include the forecast figure. Fourth-quarter revenue guidance
• Negative Sentiment: The company cited softness in the European medical-device market, a demand headwind investors will monitor despite the reaffirmed full-year targets. 2026 outlook and European market conditions

About Sotera Health

Sotera Health Company (NASDAQ: SHC) is a healthcare services company focused on sterilization, laboratory testing and infection prevention. Its services support manufacturers and providers across the medical device, pharmaceutical, tissue, food safety and other healthcare-related industries.

The company operates through three primary businesses. Sterigenics provides outsourced sterilization services, including ethylene oxide, gamma irradiation and electron-beam processing. Nelson Labs offers laboratory testing, analytical services and consulting for medical devices, pharmaceuticals and other healthcare products.